# US 2013/0156805 A1 · Chimeric momp antigen > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 2013/0156805 A1 - Document ID: US20130156805A1 - Status: Published application - Kind: A1 - Application number: 13/700,662 - Filed: 2011-05-27 - Published: 2013-06-20 - Earliest claimed: 2010-05-28 - Assignees: Spixia Biotechnology AB - Inventors: Sören Andersson; Åke Strid - Web page: https://patentgrep.com/patent/US20130156805A1 ## CPC - C07K 14/295: from Chlamydiales (O) - A61K 39/118: Chlamydiaceae, e.g. Chlamydia trachomatis or Chlamydia psittaci - A61P 31/04: Antibacterial agents - C07K 2319/40: containing a tag for immunodetection, or an epitope for immunisation - C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00) - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) - A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS ## Abstract The present invention regards polypeptides capable of eliciting an immunological response that is protective against Chlamydia trachomatis. The polypeptide comprises a first amino acid sequence which has at least 90% homology with the amino acid sequence according to SEQ ID NO: 1 and a second amino acid sequence which has at least 90% homology with the amino acid sequence according to SEQ ID NO: 2. Furthermore, production of these polypeptides and pharmaceutical compositions comprising them are also provided. ## Claims ### Claim 1 A polypeptide comprising a first amino acid sequence which has at least 90% homology with the amino acid sequence according to SEQ ID NO: 1 and a second amino acid sequence which has at least 90% homology with the amino acid sequence according to SEQ ID NO: 2, wherein said first and second amino acid sequences are separated by less than 30 amino acid residues. ### Claim 2 (depends on 1) The polypeptide according to claim 1, wherein the first amino acid sequence has at least 95% homology with the amino acid sequence according to SEQ ID NO: 1 and the second amino acid sequence which has at least 95% homology with the amino acid sequence according to SEQ ID NO: 2. ### Claim 3 (depends on 1) The polypeptide according to claim 1, which is between 107 and 132 amino acids long. ### Claim 4 (depends on 1) The polypeptide according to claim 1, wherein the first amino acid sequence and the second amino acid sequence are separated by a linker according to SEQ ID NO: 20 or SEQ ID NO: 26. ### Claim 5 (depends on 1) The polypeptide according to claim 1, wherein the first amino acid sequence is a sequence according to SEQ ID NO: 21 or SEQ ID NO: 23, and the second amino acid sequence is a sequence according to SEQ ID NO: 22 or SEQ ID NO: 24. ### Claim 6 (depends on 1) The polypeptide according to claim 1 which has at least 90% homology with the amino acid sequence according to SEQ ID NO: 3. ### Claim 7 (canceled) ### Claim 8 (depends on 6) The polypeptide according to claim 6, comprising an amino acid sequence according to SEQ ID NO: 3. ### Claim 9 (depends on 1) The polypeptide according to claim 1, fused to an amino acid sequence comprising a His tag according to SEQ ID NO: 5 or a V5 tag according to SEQ ID NO: 4. ### Claim 10 (depends on 9) The polypeptide according to claim 9, having an amino acid sequence according to SEQ ID NO: 6. ### Claim 11 (depends on 1) A compound comprising the amino acid sequence according to claim 1. ### Claim 12 (canceled) ### Claim 13 (depends on 1) A nucleic acid which encodes a polypeptide according to claim 1, which has a first nucleic acid sequence which has at least 60% homology with the nucleic acid sequence according to SEQ ID NO: 7 and a second nucleic acid sequence which has at least 60% homology with the nucleic acid sequence according to SEQ ID NO: 8, wherein said first and second nucleic acid sequences are separated by less than 90 nucleic acid residues. ### Claim 14 (canceled) ### Claim 15 (depends on 13) The nucleic acid according to claim 13, wherein the first nucleic acid sequence has at least 80% homology with the nucleic acid sequence according to SEQ ID NO: 7 and the second nucleic acid sequence has at least 80% homology with the nucleic acid sequence according to SEQ ID NO: 8. ### Claim 16 (canceled) ### Claim 17 (depends on 13) The nucleic acid according to claim 13, comprising a nucleic acid sequence according to SEQ ID NO: 9. ### Claim 18 (depends on 13) A plasmid which comprises the nucleic acid according to claim 13. ### Claim 19 (canceled) ### Claim 20 (depends on 18) A cell transformed with an expression vector, wherein the expression vector is a plasmid according to claim 18, the cell being chosen from the group consisting of a plant cell, a bacterium, a yeast cell, a fungal cell, an insect cell or a mammalian cell. ### Claim 21 (canceled) ### Claim 22 (depends on 1) A process for producing a polypeptide according to claim 1, which process comprises: culturing a cell transformed with an expression vector, wherein the expression vector is a plasmid including a nucleic acid including a first nucleic acid sequence which has at least 60% homology with the nucleic acid sequence according to SEQ ID NO: 7 and a second nucleic acid sequence which has at least 60% homology with the nucleic acid sequence according to SEQ ID NO: 8, wherein said first and second nucleic acid sequences are separated by less than 90 nucleic acid residues, the cell being chosen from the group consisting of a plant cell, a bacterium, a yeast cell, a fungal cell, an insect cell or a mammalian cell; and recovering the polypeptide. ### Claim 23 (canceled) ### Claim 24 (canceled) ### Claim 25 (canceled) ### Claim 26 (depends on 1) A vaccine against Chlamydia trachomatis, comprising a polypeptide according to claim 1. ### Claim 27 (depends on 1) A composition that prohibits infertility resulting from infection with Chlamydia trachomatis, comprising a polypeptide according to claim 1. ### Claim 28 (depends on 1) A method of treating a person infected with Chlamydia trachomatis, comprising: administering a composition that includes a polypeptide according to claim 1. ### Claim 29 (depends on 28) The method according to claim 28, wherein administering the composition comprises oral, parenteral, spray inhalation, topical, rectal, nasal, buccal, sublingual, or vaginal administration. ### Claim 30 (canceled)